Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 - Pipeline Review, H1 2016
Summary Publisher's, 'Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Pipeline Review, H1 2016', provides in depth analysis on Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-BetaHydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted pipeline therapeutics. The report provides comprehensive information on the Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-BetaHydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11beta-HSD1 or HSD11B1 or EC 1.1.1.146), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Corticosteroid 11Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development and features dormant and discontinued projects. Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Request for Sample: http://www.reportsweb.com/corticosteroid-11-beta-dehydrogenase-isozyme-1-pipeline-reviewh1-2016
Scope - The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)